|1.||Mishra, Ram K: 3 articles (01/2011 - 12/2005)|
|2.||Basurto, Enrique: 2 articles (08/2015 - 09/2014)|
|3.||Castellano, Jessica M: 2 articles (10/2007 - 12/2005)|
|4.||Mann, Amandeep: 2 articles (10/2007 - 12/2005)|
|5.||Verma, Vaneeta: 2 articles (10/2007 - 12/2005)|
|6.||Johnson, Rodney L: 2 articles (10/2007 - 12/2005)|
|7.||Pietra, C: 2 articles (09/2001 - 06/2001)|
|8.||Villetti, G: 2 articles (09/2001 - 06/2001)|
|9.||Flores, Oscar González: 1 article (08/2015)|
|10.||Hoffman, Kurt Leroy: 1 article (08/2015)|
|1.||Parkinson Disease (Parkinson's Disease)
12/09/1972 - "Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease."
01/01/1987 - "Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease."
08/01/1985 - "[Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease]."
04/15/2007 - "The neuropeptide melanocyte-inhibiting factor (MIF) or L-propyl-L-leucyl-glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. "
07/01/1985 - "Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease."
12/01/2005 - "The present study was undertaken to investigate the role of the hypothalamic tripeptide L-prolyl-L-leucyl-glycinamide (PLG) and its conformationally constrained analog 3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) in modulating agonist binding to human dopamine (DA) receptor subtypes using human neuroblastoma SH-SY5Y cells stably transfected with respective cDNAs. "
|4.||Drug-Induced Dyskinesia (Dyskinesia, Drug Induced)
|5.||Movement Disorders (Movement Disorder)
12/11/1981 - "An animal model of tardive dyskinesia was used to evaluate the potential antidyskinetic properties of the neuropeptide L-prolyl-L-leucyl-glycinamide (PLG). "
02/01/2003 - "In the present experimental paradigm, we examine the effect of L-prolyl-L-leucyl-glycinamide (PLG) co-administration with haloperidol on vacuous chewing movements (VCM) in rats-a model of tardive dyskinesia (TD) in humans. "
02/01/2003 - "Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia."
10/01/2007 - "Two melanocyte-stimulating hormone release inhibiting factor-1 (MIF-1) also known as L-prolyl-L-leucyl-glycinamide (PLG) peptidomimetic analogs, 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]-amino]-3-(butyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (A) and 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]amino]-3-(benzyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (B), were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing movements (VCMs) in rats; animal models of Parkinson's disease (PD) and human tardive dyskinesia (TD), respectively. "
05/01/1985 - "An animal model of tardive dyskinesia was used for the evaluation of potential antidyskinetic properties of the neuropeptide L-Prolyl-L-Leucyl-glycinamide (PLG) and related drugs: cyclo[glycine-(1-amino-1-cyclopentane) carbonyl]--c(CPC-Gly) and cyclo[alanine-(1-amino-1-cyclopentane) carbonyl]--c(CPC-Ala). "
|2.||3- (N- prolylamine)- 2- oxo- 1- pyrrolidineacetamide
|3.||Levodopa (L Dopa)
|7.||Glycine (Aminoacetic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)